Darolutamide for castration-resistant prostate cancer

Diogo A. Bastos, Emmanuel S. Antonarakis

Research output: Contribution to journalReview article

Abstract

The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone, enzalutamide and apalutamide) have demonstrate significant improvements in survival and important secondary endpoints. For non-metastatic castration-resistant prostate cancer, recent phase III placebo-controlled trials with enzalutamide, apalutamide and darolutamide all demonstrated benefits in improving metastasis-free survival. This review aims to summarize the clinical development of darolutamide, a novel next-generation androgen receptor antagonist, including preclinical data, clinical studies and the potential of darolutamide for the treatment of advanced prostate cancer. To date, darolutamide efficacy and tolerability has been demonstrated in the ARAMIS trial, which demonstrated an improvement in metastasis-free survival compared to placebo for non-metastatic castration-resistant prostate cancer patients with a rapid PSA doubling time. Ongoing studies will further evaluate the role of darolutamide in metastatic castration-sensitive prostate cancer in combination with docetaxel (ARASENS trial) and also in other stages of the disease.

Original languageEnglish (US)
Pages (from-to)8769-8777
Number of pages9
JournalOncoTargets and Therapy
Volume12
DOIs
StatePublished - Jan 1 2019

Fingerprint

Castration
docetaxel
Prostatic Neoplasms
Survival
Androgen Receptor Antagonists
Placebos
Neoplasm Metastasis
Androgen Receptors
Therapeutics
Pharmaceutical Preparations
MDV 3100

Keywords

  • Androgen receptor antagonist
  • Castration-resistant
  • Darolutamide
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Darolutamide for castration-resistant prostate cancer. / Bastos, Diogo A.; Antonarakis, Emmanuel S.

In: OncoTargets and Therapy, Vol. 12, 01.01.2019, p. 8769-8777.

Research output: Contribution to journalReview article

@article{3c91c7ce7208432e93572464fee0e4b2,
title = "Darolutamide for castration-resistant prostate cancer",
abstract = "The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone, enzalutamide and apalutamide) have demonstrate significant improvements in survival and important secondary endpoints. For non-metastatic castration-resistant prostate cancer, recent phase III placebo-controlled trials with enzalutamide, apalutamide and darolutamide all demonstrated benefits in improving metastasis-free survival. This review aims to summarize the clinical development of darolutamide, a novel next-generation androgen receptor antagonist, including preclinical data, clinical studies and the potential of darolutamide for the treatment of advanced prostate cancer. To date, darolutamide efficacy and tolerability has been demonstrated in the ARAMIS trial, which demonstrated an improvement in metastasis-free survival compared to placebo for non-metastatic castration-resistant prostate cancer patients with a rapid PSA doubling time. Ongoing studies will further evaluate the role of darolutamide in metastatic castration-sensitive prostate cancer in combination with docetaxel (ARASENS trial) and also in other stages of the disease.",
keywords = "Androgen receptor antagonist, Castration-resistant, Darolutamide, Prostate cancer",
author = "Bastos, {Diogo A.} and Antonarakis, {Emmanuel S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/OTT.S197244",
language = "English (US)",
volume = "12",
pages = "8769--8777",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Darolutamide for castration-resistant prostate cancer

AU - Bastos, Diogo A.

AU - Antonarakis, Emmanuel S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone, enzalutamide and apalutamide) have demonstrate significant improvements in survival and important secondary endpoints. For non-metastatic castration-resistant prostate cancer, recent phase III placebo-controlled trials with enzalutamide, apalutamide and darolutamide all demonstrated benefits in improving metastasis-free survival. This review aims to summarize the clinical development of darolutamide, a novel next-generation androgen receptor antagonist, including preclinical data, clinical studies and the potential of darolutamide for the treatment of advanced prostate cancer. To date, darolutamide efficacy and tolerability has been demonstrated in the ARAMIS trial, which demonstrated an improvement in metastasis-free survival compared to placebo for non-metastatic castration-resistant prostate cancer patients with a rapid PSA doubling time. Ongoing studies will further evaluate the role of darolutamide in metastatic castration-sensitive prostate cancer in combination with docetaxel (ARASENS trial) and also in other stages of the disease.

AB - The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone, enzalutamide and apalutamide) have demonstrate significant improvements in survival and important secondary endpoints. For non-metastatic castration-resistant prostate cancer, recent phase III placebo-controlled trials with enzalutamide, apalutamide and darolutamide all demonstrated benefits in improving metastasis-free survival. This review aims to summarize the clinical development of darolutamide, a novel next-generation androgen receptor antagonist, including preclinical data, clinical studies and the potential of darolutamide for the treatment of advanced prostate cancer. To date, darolutamide efficacy and tolerability has been demonstrated in the ARAMIS trial, which demonstrated an improvement in metastasis-free survival compared to placebo for non-metastatic castration-resistant prostate cancer patients with a rapid PSA doubling time. Ongoing studies will further evaluate the role of darolutamide in metastatic castration-sensitive prostate cancer in combination with docetaxel (ARASENS trial) and also in other stages of the disease.

KW - Androgen receptor antagonist

KW - Castration-resistant

KW - Darolutamide

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85074319881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074319881&partnerID=8YFLogxK

U2 - 10.2147/OTT.S197244

DO - 10.2147/OTT.S197244

M3 - Review article

C2 - 31695432

AN - SCOPUS:85074319881

VL - 12

SP - 8769

EP - 8777

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -